Dr. Rabi Hanna
Claim this profileCleveland Clinic Foundation
Expert in Cancer
Studies Brain Tumor
51 reported clinical trials
118 drugs studied
About Rabi Hanna
Education:
- Obtained MD from Aleppo University Faculty of Medicine, Aleppo, Syria.
Experience:
- Board certified in Pediatrics and Pediatric Hematology-Oncology.
- Completed Pediatric residency at Duke University Medical Center, Durham, North Carolina.
- Undertook Pediatric hematology-oncology fellowship at Fred Hutchinson Cancer Research Center and Seattle Children's Hospital, Washington.
- Director of Pediatric Bone Marrow Transplantation at Cleveland Clinic Children's Hospital.
- Specializes in leukemia, lymphoma, solid tumors, and inherited non-malignant disorders treatment.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Brain Tumor
Stage IV
NTRK1 positive
NTRK positive
Affiliated Hospitals
Clinical Trials Rabi Hanna is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
T Cell-Depleted Stem Cell Transplant
for Leukemia
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Recruiting1 award Phase 222 criteria
More about Rabi Hanna
Clinical Trial Related8 years of experience running clinical trials · Led 51 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments Rabi Hanna has experience with
- Cyclophosphamide
- Methotrexate
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
Breakdown of trials Rabi Hanna has run
Cancer
Brain Tumor
Leukemia
Burkitt Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rabi Hanna specialize in?
Rabi Hanna focuses on Cancer and Brain Tumor. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Rabi Hanna currently recruiting for clinical trials?
Yes, Rabi Hanna is currently recruiting for 16 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Rabi Hanna has studied deeply?
Yes, Rabi Hanna has studied treatments such as Cyclophosphamide, Methotrexate, Radiation Therapy.
What is the best way to schedule an appointment with Rabi Hanna?
Apply for one of the trials that Rabi Hanna is conducting.
What is the office address of Rabi Hanna?
The office of Rabi Hanna is located at: Cleveland Clinic Foundation, Cleveland, Ohio 44195 United States. This is the address for their practice at the Cleveland Clinic Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.